Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas

Fabricius,Eva-Maria; Wildner,Gustav-Paul; Kruse-Boitschenko,Ute; Hoffmeister,Bodo; Goodman,Simon L.; Raguse,Jan-Dirk

doi:10.3892/etm.2010.171

Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas

Authors:
- Eva-Maria Fabricius
- Gustav-Paul Wildner
- Ute Kruse-Boitschenko
- Bodo Hoffmeister
- Simon L. Goodman
- Jan-Dirk Raguse
View Affiliations

Affiliations: Clinic for Oral and Maxillofacial Surgery, Campus Virchow Hospital Charité-Universitätsmedizin, Berlin, Germany, Department of Pathology, Robert Rössle Clinic, Campus Berlin-Buch, Charité-Universitätsmedizin, Berlin, Germany, Therapeutic Area Oncology, Department of Biochemistry and Cellular Pharmacology, MERCK KGaA, Darmstadt, Germany
Published online on: December 2, 2010 https://doi.org/10.3892/etm.2010.171
Pages: 9-19

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Integrins mediate the interaction of cells with the extracellular matrix and are believed to be involved in tumor cell survival and metastasis, and in tumor angiogenesis. We used immunohistochemistry of fresh-frozen human tumor tissues to analyze the presence of integrins αvβ3, αvβ5 and α5β1, which are believed to be involved in tumor growth and migration, together with integrin ligands, vitronectin, osteopontin, fibronectin and fibrinogen, in human oral squamous cell carcinomas. Samples of squamous cell carcinomas and control tissues from patients without cancer undergoing oral or maxillofacial surgery were frozen in liquid nitrogen within 30 min of removal. Frozen sections were prepared, and the presence of integrins or ligands was visualized using standard immunohistochemistry (APAAP) with a blinded evaluation. Comparison of samples from the 40 oral cancer patients and the 20 controls revealed increased staining in tumors compared with the controls, and staining was demonstrated for αvβ3 in endothelia. αvβ5 staining was increased in the tumor samples, but this was associated with increased expression in stroma rather than in endothelia. Modestly increased expression of α5β1 was observed in the tumor samples, and this was associated with tumor cells, endothelia and stroma. Expression of ligands for the integrins varied between tissue types, with increased fibrinogen and fibronectin expression in tumor endothelia. Confirmation of the presence of these integrins and their association with tumor cells, endothelia or stroma suggests their potential for these integrins in human oral tumors. Overall, the increased expression of integrins within tumors, particularly expression associated with endothelial cells, supports the principle of selective integrin blockade as a novel anticancer strategy.

View Figures

View References

1.	Rapidis AD, Keramidas T, Panangiotopoulos H, Andressakis D and Angelopoulos AP: Tumours of the head and neck in the elderly: analysis of 190 patients. J Craniomaxillofac Surg. 26:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900. 2001. View Article : Google Scholar
3.	Döbrossy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev. 24:9–17. 2005.PubMed/NCBI
4.	Pai SI and Westra WH: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 4:49–70. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Tejani MA, Cohen RB and Mehra R: The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics. 4:173–185. 2010.PubMed/NCBI
6.	Llewellyn CD, Johnson NW and Warnakulasuriya KA: Risk factors for squamous cell carcinoma of the oral cavity in young people — a comprehensive literature review. Oral Oncol. 37:401–418. 2001.
7.	Llewellyn CD, Linklater K, Bell J, Johnson NW and Warnakulasuriya KA: Squamous cell carcinoma of the oral cavity in patients aged 45 years and under: a descriptive analysis of 116 cases diagnosed in the South East of England from 1990 to 1997. Oral Oncol. 39:106–114. 2003.PubMed/NCBI
8.	Rutt AL, Hawkshaw MJ and Sataloff RT: Laryngeal cancer in patients younger than 30 years: a review of 99 cases. Ear Nose Throat J. 89:189–192. 2010.PubMed/NCBI
9.	Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Stupp R and Ruegg C: Integrin inhibitors reaching the clinic. J Clin Oncol. 25:1637–1638. 2007.Comment on: Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD and Grossman SA: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651–1657, 2007.
11.	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Hasina R and Lingen MW: Angiogenesis in oral cancer. J Dent Educ. 65:1282–1290. 2001.
13.	Rüegg C, Dormond O and Foletti A: Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium. 9:151–160. 2002.PubMed/NCBI
14.	Erovic BM, Neuchrist C, Berger U, El-Rabadi K and Burian M: Quantitation of microvessel density in squamous cell carcinoma of the head and neck by computer-aided image analysis. Wien Klin Wochenschr. 117:53–57. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Kurtz KA, Hoffman HT, Zimmerman MB and Robinson RA: Perineural and vascular invasion in oral cavity squamous carcinoma: increased incidence on re-review of slides and by using immunohistochemical enhancement. Arch Pathol Lab Med. 29:354–359. 2005.
16.	Walsh JE, Lathers DM, Chi AC, Gillespie MB, Day TA and Young MR: Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol. 8:227–238. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Seiwert TY and Cohen EE: Targeting angiogenesis in head and neck cancer. Semin Oncol. 35:274–285. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Tucker RW, Sanford KK, Handleman SL and Jones GM: Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs. 4:722–731. 2003.PubMed/NCBI
19.	Cai W and Chen X: Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem. 6:407–428. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V and Chen X: Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov. 2:143–158. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Paolillo M, Russo MA, Serra M, Colombo L and Schinelli S: Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem. 9:1439–1446. 2009. View Article : Google Scholar
22.	Sheldrake HM and Patterson LH: Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets. 9:519–540. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Rathinam R and Alahari SK: Important role of integrins in the cancer biology. Cancer Metastasis Rev. 29:223–237. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL and Kessler H: N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists. J Med Chem. 42:3033–3040. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617. 2008.with comment: Chamberlain MC: Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma? J Clin Oncol 27: 1921–1922, 2009.
26.	Reardon DA, Nabors LB, Stupp R and Mikkelsen T: Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 17:1225–1235. 2008. View Article : Google Scholar
27.	Raguse JD, Gath HJ, Bier J, Riess H and Oettle H: Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 40:228–230. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Preissner KT: Structure and biological role of vitronectin. Annu Rev Cell Biol. 7:275–310. 1991. View Article : Google Scholar : PubMed/NCBI
30.	Seiffert D and Smith JW: The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem. 272:13705–13710. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H and Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP Complexes). J Histochem Cytochem. 32:219–229. 1984. View Article : Google Scholar
32.	Fabricius E-M, Langford A, Bier J, Hell B, Wildner G-P and Blümcke S: Immunohistochemical characterization of E48 and CD44-v6 expression in head and neck carcinomas. Cancer J. 10:325–330. 1997.
33.	Fabricius E-M, Guschmann M, Wildner G-P, Langford A, Hell B and Bier J: Divergent immunohistochemical E48 and CD44-v6 antigen expression patterns between lymph node metastases and primary squamous cell carcinomas in the head and neck region. Cancer J. 11:153–159. 1998.
34.	Fabricius E-M, Guschmann M, Langford A, Hell B and Bier J: Immunhistochemical assessment of the tumour-associated epitopes CD44v6 and E48 in tumour-free lymph nodes from patients with squamous cell carcinoma in the head-neck region. Anal Cell Pathol. 20:115–129. 2000. View Article : Google Scholar
35.	Remmele W and Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Scores (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammagewebe. Pathologe. 8:138–140. 1987.PubMed/NCBI
36.	Sachs L: Angewandte Statistik - Anwendung statistischer Methoden. 11. Auflage Springer Verlag; Berlin: pp. 8892004
37.	Jones J, Watt FM and Speight PM: Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med. 26:63–68. 1997. View Article : Google Scholar : PubMed/NCBI
38.	Thomas GJ, Jones J and Speight PM: Integrins and oral cancer. Oral Oncol. 33:381–388. 1997. View Article : Google Scholar : PubMed/NCBI
39.	Vitolo D, Ciocci L, Ferrauti P, Cicerone E, Gallo A, De Vincentiis M and Baroni CD: Alpha5 integrin distribution and TGFbeta1 gene expression in supraglottic carcinoma: their role in neoplastic local invasion and metastasis. Head Neck. 22:48–56. 2000. View Article : Google Scholar : PubMed/NCBI
40.	Thomas GJ and Speight PM: Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med. 12:479–498. 2001. View Article : Google Scholar : PubMed/NCBI
41.	Kramer RH, Shen X and Zhou H: Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev. 24:35–45. 2005. View Article : Google Scholar : PubMed/NCBI
42.	Thomas GJ, Nystrom ML and Marshall JF: Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med. 35:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
43.	Reinartz J, Schäfer B, Batrla R, Klein CE and Kramer MD: Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res. 220:274–282. 1995. View Article : Google Scholar : PubMed/NCBI
44.	Ziober BL, Silverman SS Jr and Kramer RH: Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med. 12:499–510. 2001. View Article : Google Scholar : PubMed/NCBI
45.	Lyons AJ and Jones J: Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg. 36:671–679. 2007. View Article : Google Scholar : PubMed/NCBI
46.	Villaret AB, Schreiber A, Facchetti F, Fisogni S, Lonardi S, Lombardi D, Cocco D, Redaelli de Zinis LO and Nicolai P: Immunostaining patterns of CD31 and podoplanin in previously untreated advanced oral/oropharyngeal cancer: prognostic implications. Head Neck. 32:786–792. 2010.PubMed/NCBI
47.	Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M and Beer AJ: Imaging of integrin {alpha} v{beta}3 expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro Oncol. 11:861–870. 2009.
48.	Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M and Buck CA: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 50:6757–6764. 1990.PubMed/NCBI
49.	Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ and DeWaal RM: Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 71:320–324. 1997.Erratum in: Int J Cancer 72: 706–707, 1997.
50.	Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji M and Miwa A: Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res. 21:643–647. 2001.PubMed/NCBI
51.	Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A and Deisseroth A: Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 14:346–353. 2007. View Article : Google Scholar : PubMed/NCBI
52.	Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N and Schwaiger M: Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 49:255–259. 2008. View Article : Google Scholar : PubMed/NCBI
53.	Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R and Cheresh DA: Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 4:2625–2634. 1998.PubMed/NCBI
54.	Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P and Imhof BA: Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol. 14:1126–1132. 2001. View Article : Google Scholar : PubMed/NCBI
55.	Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC and Goldbrunner RH: Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
56.	Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C and Salvatore M: Imaging of alphavbeta3 expression by a bifunctional chimeric RGD peptide not cross-reacting with alphavbeta5. Clin Cancer Res. 15:5224–5233. 2009. View Article : Google Scholar : PubMed/NCBI
57.	Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M and Rüegg C: CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 68:7323–7331. 2008. View Article : Google Scholar : PubMed/NCBI
58.	Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK and Cheresh DA: Specific cross-talk between epidermal growth factor receptor and integrin alphav-beta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 69:1383–1391. 2009. View Article : Google Scholar : PubMed/NCBI
59.	Vocca I, Franco P, Alfano D, Votta G, Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski L and Stoppelli MP: Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Int J Cancer. 124:316–325. 2009. View Article : Google Scholar : PubMed/NCBI
60.	Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C and Cohen-Jonathan Moyal E: Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 69:3308–3316. 2009. View Article : Google Scholar : PubMed/NCBI
61.	Färber K, Synowitz M, Zahn G, Vossmeyer D, Stragies R, van Rooijen N and Kettenmann H: An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 39:579–585. 2008.PubMed/NCBI
62.	Morozevich GE, Kozlova NI, Cheglakov IB, Ushakova NA, Preobrazhenskaya ME and Berman AE: Implication of alpha5-beta1 integrin in invasion of drug-resistant MCF-7/ADR breast carcinoma cells: a role for MMP-2 collagenase. Biochemistry. 73:791–796. 2008.PubMed/NCBI
63.	Morozevich G, Kozlova N, Cheglakov I, Ushakova N and Berman A: Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle. 8:2219–2225. 2009. View Article : Google Scholar : PubMed/NCBI
64.	Lee MY, Huang JP, Chen YY, Aplin JD, Wu YH, Chen CY, Chen PC and Chen CP: Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoS One. 4:E69132009. View Article : Google Scholar : PubMed/NCBI
65.	Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP and Knolle J: Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 127:1329–1335. 2009. View Article : Google Scholar
66.	Morgan MR, Byron A, Humphries MJ and Bass MD: Giving off mixed signals-distinct functions of alpha5beta1 and alphavbeta3 integrins in regulating cell behaviour. IUBMB Life. 61:731–738. 2009. View Article : Google Scholar : PubMed/NCBI
67.	Carter A: Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst. 102:675–677. 2010. View Article : Google Scholar : PubMed/NCBI
68.	Wittekind Ch, Meyer HJ and Bootz F: TNM Klassifikation Maligner Tumoren. UICC International Union Against Cancer. 6. Aufl. Korr. Nachdruck. Kopf- und Halstumoren; pp. 19–52. 2005
69.	Cheresh DA and Spiro RC: Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 262:17703–17711. 1987.PubMed/NCBI
70.	Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela R and Sheppard D: Role of the integrin alpha v beta 6 in cell attachment to fibronectin – heterologous expression of intact and secreted forms of the receptor. J Biol Chem. 269:6940–6948. 1994.
71.	Wayner EA, Carter WG, Piotrowicz RS and Kunicki TJ: The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellaular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoprotein Ic-IIa. J Cell Biol. 107:1881–1891. 1988.
72.	Seiffert D, Ciambrone G, Wagner NV, Binder BR and Loskutoff DJ: The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem. 269:2659–2666. 1994.PubMed/NCBI